{"title":"Quebec prostate cancer mortality dropped in 1996.","authors":"F Meyer, L Moore, I Bairati, Y Fradet","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To monitor incidence and mortality rates of prostate cancer in the province of Quebec.</p><p><strong>Design: </strong>Population-based incidence and mortality trends.</p><p><strong>Setting: </strong>Entire population of the province of Quebec between 1979 and 1996.</p><p><strong>Main outcome measures: </strong>Age-standardized incidence rates and mortality for prostate cancer.</p><p><strong>Results: </strong>Prostate cancer mortality increased regularly until 1989, were stable between 1989 and 1995 and dropped in 1996 by 15%. Incidence rates increased steadily from 1989 until 1993 by an average of 9% per year.</p><p><strong>Conclusion: </strong>The rise in incidence is due to the increasing use of prostate specific antigen as a screening test for prostate cancer. The reasons for the reduction in prostate cancer mortality are unknown but are likely to reflect improved treatment modalities.</p>","PeriodicalId":79570,"journal":{"name":"Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC","volume":"2 4","pages":"163-6"},"PeriodicalIF":0.0000,"publicationDate":"1998-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To monitor incidence and mortality rates of prostate cancer in the province of Quebec.
Design: Population-based incidence and mortality trends.
Setting: Entire population of the province of Quebec between 1979 and 1996.
Main outcome measures: Age-standardized incidence rates and mortality for prostate cancer.
Results: Prostate cancer mortality increased regularly until 1989, were stable between 1989 and 1995 and dropped in 1996 by 15%. Incidence rates increased steadily from 1989 until 1993 by an average of 9% per year.
Conclusion: The rise in incidence is due to the increasing use of prostate specific antigen as a screening test for prostate cancer. The reasons for the reduction in prostate cancer mortality are unknown but are likely to reflect improved treatment modalities.